A Combined Phase 1 + 2 Clinical Trial Evaluating the Safety and Efficacy of BC-DN-01 in the Treatment of Painful Diabetic Peripheral Neuropathy
Latest Information Update: 09 May 2019
Price :
$35 *
At a glance
- Drugs Benfotiamine (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors BioChemics
- 24 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 20 Feb 2013 New trial record